Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
Two different enzyme preparations, agalsidase alfa (Replagal(TM), Shire) and beta (Fabrazyme(TM), Genzyme), are registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase preparations administered at identical protein dose in a randomized contr...
Main Authors: | Anouk C Vedder, Gabor E Linthorst, Gunnar Houge, Johannna E M Groener, Els E Ormel, Berto J Bouma, Johannes M F G Aerts, Asle Hirth, Carla E M Hollak |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2007-07-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC1913555?pdf=render |
Similar Items
-
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
by: Hollak Carla EM, et al.
Published: (2011-10-01) -
Update on role of agalsidase alfa in management of Fabry disease
by: Uma Ramaswami
Published: (2011-03-01) -
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
by: Michael Beck, et al.
Published: (2015-06-01) -
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
by: Kazuya Tsuboi, et al.
Published: (2017-06-01) -
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
by: Goláň L, et al.
Published: (2015-07-01)